Long/short equity, research analyst, biotech, healthcare

Why MannKind Is My 2014 Short Pick In Healthcare

So it's been a long series, and I want to thank everyone for checking it out. And if you missed it, my 'home run' pick in healthcare, Ocera Therapeutics (NASDAQ:OCRX) jumped over 25% since the article was published, although it gave back some of those gains at closing yesterday. And Acadia Pharmaceuticals (NASDAQ:ACAD) has been lagging behind the sector as predicted, and the short thesis behind Questcor (QCOR) is getting pummeled as well. Finally, Novavax (NASDAQ:NVAX) has soared over 15% since calling the company a top buyout pick this year.

I saved my short pick(s) for last because these candidates have generally produced the best and fastest gains in my career. So...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details